PET Study of the Nicotinic System in Epilepsy
NCT03268369 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48
Last updated 2017-08-31
Summary
Mutations in neuronal nicotinic acetylcholine receptors (nAChRs) have been identified in the autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Despite the demonstration of a gain of function of the mutated receptors, the precise mechanisms leading to this nocturnal epilepsy are still unknown. In 2006 the investigators studied the nAChR cerebral distribution in a group of patients with ADNFLE carrying a nAChR mutation, by a PET-scan using \[18F\]-F-A-85380, a ligand with a high affinity and specificity for alpha4beta2 nicotinic receptors. The study showed a different pattern of brain distribution of the radiotracer in the ADNFLE patients when compared to a group of control subjects, with a significant increase of nicotinic receptor density in the patients in mesencephalon and cerebellum (Picard et al., Brain 2006). Based on the known biochemical and cellular circuits in the brainstem, these results suggest that the nAChR density increase in mesencephalon is involved in the pathophysiology of ADNFLE through the role of brainstem ascending cholinergic systems in arousal. The follow-up step consists of extending this examination to other forms of epilepsy, in order to verify the specificity of the hyperfixation pattern for ADNFLE, and search for a potential involvement of nicotinic receptors in other forms of epilepsy. The investigators aim to study 5 groups of subjects: control subjects (Group 1, 20 subjects); patients with a non lesional partial epilepsy and a predominance of diurnal seizures (Group 2, 12 subjects); patients with an idiopathic generalized epilepsy (Group 3, 12 subjects); patients with nocturnal frontal lobe epilepsy (Group 4, 3 subjects) and epileptic patients with vagal nerve stimulation (Group 5, 1 subject). For each patient, a cerebral MRI, \[18F\]- fluorodeoxyglucose (FDG) PET/CT and \[18F\]-F-A-85380 PET/CT examinations are planned. The investigators will perform data analyses on volume of distribution (Vt) parametric images which will be based on the ratio of brain tissue to unchanged F-A-85380 plasma at equilibrium. Statistical parametric mapping (SPM2) will be used to further study the parametric PET images. This study is primarily dedicated to demonstrate that the pattern of hyperfixation that was obtained in ADNFLE patients is specific for this disorder and does not constitute a common pattern to various forms of epilepsy. The investigators will also search for a possible involvement of the nAChRs in other forms of epilepsy.
Conditions
Interventions
- RADIATION
-
MRI of the brain
to eliminate a structural intra-cerebral lesion
- RADIATION
-
PET scan [18F]F-A-85380
exam performed after iv injection of 200 MBq \[18F\]F-A-85380
- RADIATION
-
PET scan [18F]FDG
exam performed after iv injection of 200 MBq \[18F\]FDG
Sponsors & Collaborators
-
Fabienne PICARD
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2012-02-29
- Primary Completion
- 2015-11-30
- Completion
- 2015-11-30
More Related Trials
-
Peripheral Benzodiazepine Receptors (PBR28) Brain PET Imaging With Lipopolysaccharide Challenge for the Study of Microglia Function in Alzheimer's Disease
NCT04057807 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
(18)F-FDG PET Database of Adult Healthy Individuals
NCT03100227 ·Status: COMPLETED ·Phase: NA
-
A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome
NCT07013331 ·Status: RECRUITING ·Phase: NA
-
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
NCT02062099 ·Status: COMPLETED ·Phase: PHASE1
-
Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease
NCT04718207 ·Status: COMPLETED
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Metabolic Abnormalities in Children With Epilepsy
NCT00001325 ·Status: COMPLETED
-
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209 ·Status: TERMINATED ·Phase: PHASE1
-
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
NCT04150198 ·Status: RECRUITING ·Phase: NA
-
PET Changes in Alzheimer's Disease (AD)
NCT00094913 ·Status: UNKNOWN
-
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01209156 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease
NCT05911178 ·Status: RECRUITING ·Phase: NA
-
18F-AV-1451 PET Imaging in TBI
NCT02512029 ·Status: WITHDRAWN ·Phase: PHASE1
-
Exploration of Cluster Headache in a PET-MRI Study
NCT05084469 ·Status: UNKNOWN
-
PET Scan in Patients With Neurocardiologic Disorders
NCT00001418 ·Status: COMPLETED
-
Isotopic Imaging for Prodromal Alzheimer's Disease
NCT01231295 ·Status: COMPLETED
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·Status: RECRUITING ·Phase: PHASE3
-
Brain Blood Flow Studies of Language and Memory
NCT00001288 ·Status: COMPLETED
-
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
NCT01826110 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET
NCT07100470 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873 ·Status: RECRUITING ·Phase: PHASE1
-
Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders
NCT00001362 ·Status: COMPLETED
-
Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis
NCT00563537 ·Status: UNKNOWN ·Phase: PHASE1
-
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
NCT01812213 ·Status: TERMINATED ·Phase: PHASE2
-
Neuroinflammation and Cognitive Decline in Alzheimer Disease
NCT02377206 ·Status: COMPLETED ·Phase: EARLY_PHASE1